Background: Periostin (osteoblast-specific factor OSF-2) is a secreted protein occurring in seven known isoforms, and it is involved in a variety of biological processes in osteology, tissue repair, oncology, cardiovascular and respiratory systems or allergic manifestations. To analyze functional aspects of periostin, or the ability of periostin as potential biomarker in physiological and pathological conditions, there is the need for a precise, well-characterized assay that detects periostin in peripheral blood.
of signaling pathways such as the Akt/PKB and FAK-mediated pathway. 6 The C-terminus is prone to alternative splicing which results in seven periostin isoforms with molecular masses from 80 to 93 kDa ( Figure 1 ). It binds to extracellular matrix molecules and regulates cellmatrix organization.
6
Periostin is associated with a variety of tissues and pathologies. 7 It is involved in the epithelial-mesenchymal transition in the course of cardiac development 8 and cancer. 9 It is re-expressed after myocardial injury, 10 it participates in myocardial remodeling and it is induced after vascular 11 and skeletal muscle injury. 12 In a cohort of patients with ovarian tumors it has been shown that periostin promotes tumor metastatic growth and angiogenesis. 13 In bone,
periostin has a general function in homeostasis 14 and it is upregulated after bone fracture or in response to mechanical stress when bone development and remodeling is required. 15 It acts on bone formation through an increase in osteoblast function as it is able F I G U R E 1 Schematic representation of human periostin, localization of epitopes recognized by the antibodies used in the periostin ELISA, and alignment of all seven currently known periostin isoforms. A, Top: Epitope recognized by the monoclonal coating antibody (m_e1). Bottom: Epitopes recognized by the polyclonal detection antibody (five major epitopes, p_e1 to p_e5) (x-axes: schematic representation of periostin sequence; y-axes: fluorescence units). B, Protein sequence alignment of the C-terminal domain of seven human periostin isoforms. Identical amino acids are indicated by dots and gaps are indicated by dashes. Two major epitopes recognized by the detection antibody (p_e4, p_e5) are localized in the C-terminal domain and are framed in gray C-terminal domain to modulate Wnt-beta-catenin signaling by downregulating sclerostin expression. 16 There is evidence that serum periostin could be a new biological marker of fracture risk. 14 Moreover, a pathological expression of periostin is observed in bone diseases like fibrous dysplasia. 17 In cutaneous wound healing periostin is described to act on keratinocyte proliferation, for example periostin-deficient mice showed delayed wound closure and re-epithelialization. 18 Periostin has further been shown to be a downstream molecule of the T H 2 cytokines IL-4 and IL-13 19 and it is involved in many aspects of T H 2-driven asthma or eosinophilic inflammation. [20] [21] [22] In addition, periostin has been related to atopic dermatitis, 23 allergic rhinitis, and chronic rhinosinusitis. 24 In order to evaluate the function of periostin and its potential as a biochemical marker, a precise, well-defined assay to screen peripheral blood is needed. Hence, we developed a sandwich ELISA based on well-characterized monoclonal and affinity-purified polyclonal anti-human periostin antibodies with mapped epitopes and defined cross-reactivities to human periostin isoforms to provide best possible insight into the antibody-analyte reaction. 25 We analyzed and validated the assay based on the principles of bioanalytical validation defined by the ICH harmonized tripartite guideline Q2 (R1) and by the EMEA guideline of bioanalytical method validation.
| MATERIAL AND METHODS

| Serum and plasma samples
Venous blood samples were collected from apparently healthy individuals and from patients suffering from asthma or cardiovascular disease. Sample characterization and patients' clinical data from the latter are summarized in Table 1 . Blood samples were obtained using blood collection tubes for serum and plasma after informed consent was given. After incubation at room temperature, collection tubes were centrifuged (eg 10 minutes at 2000×g at 4°C) and the obtained serum and plasma was stored at −20°C or lower. Samples were analyzed in an anonymized manner. GmbH, Heidelberg, Germany). After blocking, the array was incubated overnight with the diluted antibody (1μg/mL). 
| Epitope mapping of anti-human periostin antibodies used for sandwich ELISA development
| Sequence alignment of human periostin isoforms
Sequences of the C-terminal regions of human periostin isoforms (UniProt entry: Q15063) were aligned with the multiple sequence alignment program ClustalW 26 and edited and visualized with GeneDoc. 
| Setup of the periostin sandwich ELISA
Plates were coated with 150 μL of the mouse monoclonal anti-human periostin coating antibody, sealed and incubated for one hour at room temperature (18-26°C). After aspiration of the coating solution, wells were blocked with 300 μL per well of blocking solution overnight at 4°C. Thereafter, each well was aspirated and dried for three hours.
The assay was calibrated with mouse myeloma-derived recombinant human periostin isoform 1. Calibrator (0-4000 pmol/L) was spiked into periostin-depleted serum matrix which was produced by immune affinity chromatography. Standards, control sera, and human serum or plasma samples were diluted 1+50 with protein buffered assay buffer. 150 μL of standard, samples, or controls were added to the dried wells and incubated for 2 hours at room temperature. Plates were then washed five times with wash buffer before adding 150 μL of the biotinylated goat polyclonal anti-human periostin antibody and incubated for 2 hours at room temperature. Plates were washed five times as described before.
In order to detect bound biotinylated detection antibody, 150 μL of the conjugate solution, consisting of horseradish peroxidase-labeled streptavidin, was added to each well. The mixture was incubated for 1 hour at room temperature to allow the formation of the biotin-streptavidin complex. After incubation, wells were washed five times, and substrate solution was added. The final incubation step was performed in the dark, and the reaction was stopped after 30 minutes with stop solution. The absorbance was measured with a microplate reader (BioTec, Winooski, VT, USA) at 450 nm with an absorbance correction at 630 nm.
| Assay evaluation of the human periostin sandwich ELISA and quantification of periostin levels in apparently healthy and diseased subjects
The human periostin ELISA was validated according to ICH and EMEA guidelines. Assay parameters such as the definition of the assay range (including the lowest level of quantification as well as the level of detection), the analysis of precision, the specificity, the accuracy or spike recovery, and the dilution linearity in different sample matrices (serum, EDTA plasma, citrate plasma, heparin plasma) were assessed. The stability of endogenous periostin in human serum and plasma was tested, and the distribution of periostin concentration in different sample matrices (serum, EDTA plasma, citrate plasma, heparin plasma) from apparently healthy subjects was determined. Serum periostin levels of healthy subjects were compared with serum levels of asthmatic patients and of patients suffering from cardiovascular disease.
| Statistics
Differences of periostin concentrations measured in different sample cohorts were assessed by Mann-Whitney U or Wilcoxon test using GraphPad Prism 6 software. Values of P<.05 were considered as significant.
| RESULTS
| Epitope mapping and analysis of crossreactivity of the coating and detection anti-human periostin antibodies
Linear epitopes of the monoclonal mouse anti-periostin antibody and the polyclonal goat anti-periostin antibody employed in the assay were mapped with microarray technology, where binding intensities shows sequence variations between the isoforms from 71% to 98%
( Figure 1B) . Protein sequence alignment reveals that epitope 5 (p_e5: RISTGGGE) is identical between all isoforms, but epitope 4 (isoform 1: p_e4: KTEGPTLT) varies in isoforms 3 and 5, and is even deleted in isoform 2, 4, 6, and 7 ( Figure 1B) . Therefore, all epitopes that are recognized by the polyclonal detection antibody are conserved between the isoforms except of epitope p_e4.
To assess if the detection antibody is still able to detect all currently known human periostin isoforms, isoforms 1 to 3 covering all epitope variants of the seven described isoforms were selected for further testing. Commercially available recombinant isoforms 1 to 3 were analyzed by SDS-PAGE, and staining revealed varying amounts of periostin and different levels of purities. Matched amounts of isoform 1 to 3 were separated in two concentrations under reducing conditions by SDS-PAGE, and staining with colloidal coomassie revealed a 90 kDa band in all three periostin isoforms ( Figure 2A ). Additionally, smaller bands representing impurities that have not been removed by the manufacturer's purification procedure were stained. After nitrocellulose transfer and probing with the polyclonal goat detection antibody, the 90 kDa band was identified as human periostin. All three isoforms were recognized by the detection antibody, and the intensities of reactivities correlated with the applied protein amounts ( Figure 2B ).
| Principle of the sandwich ELISA assay, description of the assay range and definition of the assay limits
The setup of the periostin sandwich ELISA consists of a monoclonal mouse coating antibody used for capturing endogenous or recombinant human periostin, and a labeled polyclonal goat antibody used for detection as described before. The assay uses recombinant human periostin isoform 1 as calibrator. The calibrator curve was evaluated with a 4PL algorithm and is shown in Figure 3A . For all seven standards, the coefficient of variation in percent (% CV) for OD values as well as for calculated concentrations was ≤2% (data not shown). The dynamic range of the assay is set between 125 pmol/L and 4000 pmol/L. For the calculation of the lower limit of quantification (LLOQ), which is defined as the lowest concentration that can be measured with an acceptable accuracy and precision, ie with a CV ≤25%, standard 2 was diluted in twofold steps in protein-buffered assay buffer.
Five replicas per dilution were measured and the CV (%) was calcu- 
| Intra-assay and inter-assay precision
For the determination of the repeatability, intra-assay precision was (Table 2) . Inter-assay precision resulted in an average of 251 pmol/L with a SD of 11.2 pmol/L for the low sample (sample 1) and of 1996 pmol/L (SD=111.5 pmol/L) for the high sample (sample 2). The determined CV values were slightly higher than the CV values from the intra-assay precision as the low sample (sample 1) had a CV of 4%, and the sample from the high calibration range (sample 2) showed a CV of 6% (Table 2 ).
| Characterization of the assay specificity
To exclude potential interference with unspecific matrix components, the coating antibody was subjected to specificity testing. Samples from apparently healthy subjects (n=14) were measured with or without preceding addition of a 10-fold molar excess of coating antibody, and detection of endogenous periostin was performed as described in the material and methods section. Percent competition was calculated and values from 14 patients varied between 93% and 100% (mean value 98%) ( Table 3 ). All competition values were >90% hence demonstrating that the assay is highly specific for human endogenous periostin.
| Determination of accuracy/spike recovery in different sample matrices
In order to determine the accuracy of the assay, different sample matrices of apparently healthy individuals (serum, n=7; EDTA plasma, n=8; citrate plasma, n=8; heparin plasma, n=7) containing varying amounts of endogenous periostin were spiked with a mid (500 pmol/L) and a high (2000 pmol/L) concentration of recombinant human periostin isoform 1, and recovery was assayed. Mean spike recovery per sample matrix was calculated. Spiking with 500 pmol/L recombinant periostin led to a mean recovery of 106% for serum, 98% for EDTA plasma, 102% for citrate plasma, and 92% for heparin plasma ( Figure 4A, top) . When a high concentration (2000 pmol/L) of recombinant periostin isoform 1 was spiked in the four different matrices a mean recovery of 95% for serum, 83% for EDTA plasma, 91% for citrate plasma and 85% for heparin plasma was calculated ( Figure 4A, bottom) . Percent recoveries reside within the accepted range of 80% to 120% indicating high accuracy of the assay.
| Definition of dilution linearity
Samples (serum, n=12; EDTA plasma, n=4; citrate plasma, n=4; heparin plasma, n=4) with endogenous periostin levels in a mid dynamic range were tested. Samples were pre-diluted 1+50 as described earlier, and then diluted 1+1 and 1+3 in protein-buffered assay buffer. Percent recovery after dilution was calculated. Sample dilution analysis showed linear results across the dynamic assay range (125 pmol/L to 4000 pmol/L). After a 1+1 dilution, the mean recovery was very homogenous and ranged for plasma (EDTA, citrate, heparin) and serum between 95% and 101% respectively ( Figure 4B, top) . After a 1+3 dilution, the mean recovery ranged between 105% for serum and 117% for citrate plasma. Heparin plasma showed slightly higher mean recovery value of 126%, indicating the influence of a matrix effect in a 1+3 dilution ( Figure 4B, bottom) .
| Freeze/thaw cycle stability of endogenous periostin
For the determination of stability of endogenous periostin in different matrices (serum, EDTA plasma, citrate plasma, heparin plasma), specimen were taken from four subjects containing endogenous periostin levels. Samples were stressed by zero (reference), two, three, and four cycles of freezing at −20°C and thawing. Samples were transferred to room temperature prior to testing. Mean values per matrix were calculated and were related to the initial state (reference) as percent recoveries of the sample (zero freeze/thaw; reference value defined T A B L E 2 Determination of the intra-assay and the inter-assay precision
Mean (pmol/L) SD (pmol/L) Precision (% CV)
Intra-assay (n=5) T A B L E 3 Characterization of assay specificity as 100%) ( Figure 5 ). Serum shows percent recovery of 100% after two cycles of freeze/thaw, and slight deviation after three (103%) and four (98%) freeze/thaw cycles. Recovery is similar in plasma samples.
EDTA plasma shows recovery of 91% after two freeze/thaw cycles and fluctuates to 93% (three cycles) and 90% (four cycles). Citrate plasma measures 93% recovery after two freeze/thaw cycles, and deviates from 91% to 97% after three and four cycles. Heparin plasma shows 96% recovery after two cycles, another 96% after three, and 99% after four cycles of freeze/thaw ( Figure 5 ). These very slight variations after two (plasma) or three (serum) freeze thaw cycles in all four measured matrices allow the conclusion that endogenous periostin levels are stable for at least four cycles of freezing and thawing of samples.
| Quantification of endogenous periostin in different sample matrices of apparently healthy subjects and diseased individuals
Four different matrices (serum, n=24; citrate plasma, n=24; EDTA plasma, n=20; heparin plasma, n=20) from blood samples of appar- In addition, periostin levels were measured in a group of serum samples from asthma (n=10) and cardiovascular disease patients (n=10) vs age and gender matched control patients (n=18). Diseased samples were related to the median of control patients as z-scores, and the differences between the diseased sample groups and the control group were tested for statistical significance with Mann-Whitney U or Wilcoxon testing. There was no significant difference between the control and the asthma group (P>.05) ( Figure 6B ). However, when
we compared the control group with the group of samples from patients with cardiovascular disease a significant increase in the population with cardiovascular disease was observed (P<.05) ( Figure 6B ).
| DISCUSSION
Periostin has been discussed as a promising biomarker to determine bone fracture risk, 14 or for T H 2-associated asthma and eosinophilic inflammation to select patients who may benefit from IL-13-targeted treatment.
21,28,29 
Stability of endogenous periostin
In this study, we describe the development and performance of a sandwich ELISA assay to quantify endogenous periostin in human serum and plasma. The assay is standardized with periostin isoform 1.
However, the characterization of the antibodies employed in the assay shows that all known human periostin isoforms can be detected. In of the polyclonal detection antibody are sufficient to detect all seven currently known isoforms we used commercially available recombinant periostin isoforms 1, 2, and 3 which cover all epitope variants of epitope p_e4 of the seven known isoforms. We could show that the employed detection antibody reacts with the nitrocellulose-blotted proteins in equal intensities, there was no significant difference between the isoforms.
In contrast, other commercial periostin sandwich ELISA assays (USCN, China; Adipogen, Switzerland) do not reveal epitope information. The assay from USCN is set up with a polyclonal antibody raised against the first fasciclin-1 domain (position 97 -230) and it is supposed that all isoforms can be detected. 30 The ELISA assay from
Adipogen uses two monoclonal antibodies of unknown epitope specificity. 14 According to the manufacturer they bind to isoform 1 and 2
and they are expected to bind to additional isoforms.
Our assay is a highly specific and precise tool to detect endoge- suffering from moderate-to-severe asthma into periostin-low and periostin-high patients. 21, 28 As threshold for this classification a median periostin value of 50 ng/mL was chosen. This value was defined in a clinical phase II study (MILLY study) analyzing the usefulness of serum periostin as a biomarker to select asthmatic patients who are more likely to benefit from treatment with lebrikizumab, a therapeutic humanized anti-IL-13 antibody. 21 The ARCHITECT ® Periostin assay 32 was used in a similar setting to screen serum samples of asthmatic patients for periostin concentrations over a predefined threshold who are most likely to benefit from treatment with IL-13
antagonists. 29 Fingleton et al. used the Elecsys ® clinical trial version in a crosssectional study to determine serum periostin levels in adult patients with symptoms of obstructive airway disease. 34 They reproduced cut-off periostin levels of asthmatic patients from the MILLY, LUTE, and VERSE studies 21, 28 by describing a median of 53.7 ng/mL. The same study also described that there was no significant difference between periostin levels of asthmatic and non-asthmatic patients (median non-asthmatics: 54.6 ng/mL), 34 a result that was further confirmed by Caswell-Smith et al. 35 Serum periostin levels from asthmatic
patients measured with our ELISA agree with these data, we also do not show significant differences between the asthmatic and nonasthmatic group.
As serum levels of periostin have further been described to increase in response to cardiovascular injury and hypertension, 11, 36, 37 we analyzed a panel of samples from patients with cardiovascular disease (n=10). Consistent with literature we observed significantly increased serum periostin levels in these samples.
We defined periostin concentrations in apparently healthy sub- ng/mL as reported by Fingleton et al. 34 and Caswell-Smith et al. 35 respectively. We further analyzed assay ranges of the periostin sandwich ELISA assays from USCN and Adipogen. They were applied to investigate the correlation of serum or plasma periostin with spine and hip areal bone mineral density in post-menopausal women.
39,40
In the study by Kim et al. the Adipogen assay measured mean plasma periostin concentrations of 29.2 ng/mL in a group of healthy control subjects without osteoporotic fracture. 39 We obtained comparable values in an apparently healthy population with our periostin assay.
In contrast, Anastasilakis et al. report mean serum periostin levels of 250 ng/mL from apparently healthy control women with normal bone mass obtained with the USCN assay. 40 These values are beyond the assay range of our assay and of the Elecsys ® assay, which may be explained by the lack of standardization in research and commercial assays.
In conclusion, we developed a reliable, accurate, and robust tool for the quantitative determination of all currently known isoforms of periostin in human healthy and diseased samples. Unlike other commercially available immunoassays, we provide in depth epitope information of the employed antibodies. While the automated immunoassays Elecsys ® and ARCHITECT ® detect periostin in serum, we are able to quantify periostin concentrations in serum and in various plasma matrices (citrate, EDTA, heparin). Therefore, this assay is a useful tool to further investigate functional aspects of periostin and its potential as a biomarker in various clinical settings.
